85 Israel has long been recognised as one of the world’s most concentrated centres of technological innovation. Over the past decade, that reputation has increasingly extended to the healthcare and life sciences sectors. A distinctive blend of engineering talent, advanced clinical infrastructure and sophisticated health-data systems has cultivated an ecosystem that consistently attracts global strategic interest. For US healthcare companies and life sciences investors seeking international growth, partnerships, or acquisition opportunities, Israel stands out in 2025 and 2026 as a highly compelling market. It offers a rare combination of scientific capability, credible clinical-validation environments and an active cross-border M&A landscape. However, successfully entering Israel’s healthcare and life sciences sector requires a clear understanding of the country’s regulatory environment, payer structure and transaction dynamics. Investors who perform best view Israel not merely as a one-off source of innovation, but as a strategic market where long-term collaboration, clinical validation and scalable growth converge. Why Israel - and why now? The first question many US healthcare investors ask is simple: why Israel, and why now? The Israeli ecosystem offers an unusually dense innovation environment that brings together engineering talent, clinical validation, regulatory sophistication and commercial scalability within a relatively small geography. That concentration often enables technologies to move through the healthcare innovation cycle more efficiently than in many other markets. From the perspective of a corporate and M&A lawyer advising US and other international buyers entering the Israeli market, the most compelling “why Israel” case for 2025-2026 is straightforward: Israel compresses the healthcare innovation cycle - from engineering and clinical validation to realworld evidence and commercial scale - into a highly integrated ecosystem. Innovation density. Israel has built a deep life sciences foundation across medical devices, digital health, diagnostics and therapeutics. It boasts thousands of active companies, including a significant cohort that is commercially mature and exportoriented. Importantly for US strategic buyers, this is not merely a “science fair” ecosystem; global regulatory foresight and go-to-market discipline are typically embedded from the outset. Hospital infrastructure as an innovation platform. Israel’s leading medical centres are not only highquality clinical environments, but are also increasingly structured to run pilots, validate products and partner with industry. For example, Sheba Medical Center is consistently ranked among the world’s leading hospitals, with other Israeli centres also featuring prominently in international rankings. For US companies, this translates into direct access to credible clinical partners, respected clinical researchers, and practical pathways for generating the evidence needed to support international regulatory and commercial strategies. For US healthcare companies and life sciences investors seeking international growth, partnerships, or acquisition opportunities, Israel stands out in 2025 and 2026 as a highly compelling market.” ISRAEL — HEALTHCARE
RkJQdWJsaXNoZXIy MjgzNzA=